What's Happening?
Researchers at Weill Cornell Medicine and Duke University have found that prostate-specific antigen (PSA) levels may not always accurately reflect the progression of prostate cancer. The study, published in the Journal of Clinical Oncology, analyzed data
from over 2,500 men involved in two phase 3 clinical trials, ARCHES and PROSPER, which tested the drug enzalutamide. This drug targets the androgen receptor, a protein that prostate cancer cells use to grow. The trials assessed cancer spread or growth through imaging scans alongside changes in PSA levels. The findings revealed that up to 25% of patients experienced cancer progression detectable by imaging, despite stable or low PSA levels. This suggests that relying solely on PSA levels could delay the detection of significant disease growth.
Why It's Important?
The study's findings challenge the long-standing reliance on PSA levels as a primary tool for monitoring prostate cancer progression. This could have significant implications for patient care, as undetected cancer growth can lead to worse outcomes. The research suggests that patients receiving modern targeted therapies, such as enzalutamide, may benefit from periodic imaging in addition to PSA monitoring. This could lead to changes in clinical guidelines, emphasizing the need for more comprehensive monitoring strategies to improve patient outcomes. The study highlights the potential for some tumors to grow independently of androgen receptor signaling, which may require new approaches to treatment and monitoring.
What's Next?
The researchers propose that future clinical guidelines should reconsider how PSA increases define cancer advancement and provide clearer recommendations for imaging frequency. This could involve integrating periodic imaging into standard care practices for patients receiving potent androgen receptor inhibitors. Further investigation into the mechanisms that allow tumors to grow without increasing PSA levels is needed. This could lead to the development of new therapeutic strategies and monitoring techniques to better manage advanced prostate cancer.
